24
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Widespread transneuronal propagation of α-synucleinopathy triggered in olfactory bulb mimics prodromal Parkinson’s disease

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Rey et al. generate a mouse model for the spatial propagation of α-synuclein pathology that mimics prodromal Parkinson's disease.

          Abstract

          Parkinson’s disease (PD) is characterized by the progressive appearance of intraneuronal Lewy aggregates, which are primarily composed of misfolded α-synuclein (α-syn). The aggregates are believed to propagate via neural pathways following a stereotypical pattern, starting in the olfactory bulb (OB) and gut. We hypothesized that injection of fibrillar α-syn into the OB of wild-type mice would recreate the sequential progression of Lewy-like pathology, while triggering olfactory deficits. We demonstrate that injected α-syn fibrils recruit endogenous α-syn into pathological aggregates that spread transneuronally over several months, initially in the olfactory network and later in distant brain regions. The seeded inclusions contain posttranslationally modified α-syn that is Thioflavin S positive, indicative of amyloid fibrils. The spreading α-syn pathology induces progressive and specific olfactory deficits. Thus, we demonstrate that propagating α-syn pathology triggered in the OB is functionally detrimental. Collectively, we have created a mouse model of prodromal PD.

          Related collections

          Most cited references36

          • Record: found
          • Abstract: found
          • Article: not found

          Stages in the development of Parkinson's disease-related pathology.

          The synucleinopathy, idiopathic Parkinson's disease, is a multisystem disorder that involves only a few predisposed nerve cell types in specific regions of the human nervous system. The intracerebral formation of abnormal proteinaceous Lewy bodies and Lewy neurites begins at defined induction sites and advances in a topographically predictable sequence. As the disease progresses, components of the autonomic, limbic, and somatomotor systems become particularly badly damaged. During presymptomatic stages 1-2, inclusion body pathology is confined to the medulla oblongata/pontine tegmentum and olfactory bulb/anterior olfactory nucleus. In stages 3-4, the substantia nigra and other nuclear grays of the midbrain and forebrain become the focus of initially slight and, then, severe pathological changes. At this point, most individuals probably cross the threshold to the symptomatic phase of the illness. In the end-stages 5-6, the process enters the mature neocortex, and the disease manifests itself in all of its clinical dimensions.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            alpha-Synuclein is phosphorylated in synucleinopathy lesions.

            The deposition of the abundant presynaptic brain protein alpha-synuclein as fibrillary aggregates in neurons or glial cells is a hallmark lesion in a subset of neurodegenerative disorders. These disorders include Parkinson's disease (PD), dementia with Lewy bodies (DLB) and multiple system atrophy, collectively referred to as synucleinopathies. Importantly, the identification of missense mutations in the alpha-synuclein gene in some pedigrees of familial PD has strongly implicated alpha-synuclein in the pathogenesis of PD and other synucleinopathies. However, specific post-translational modifications that underlie the aggregation of alpha-synuclein in affected brains have not, as yet, been identified. Here, we show by mass spectrometry analysis and studies with an antibody that specifically recognizes phospho-Ser 129 of alpha-synuclein, that this residue is selectively and extensively phosphorylated in synucleinopathy lesions. Furthermore, phosphorylation of alpha-synuclein at Ser 129 promoted fibril formation in vitro. These results highlight the importance of phosphorylation of filamentous proteins in the pathogenesis of neurodegenerative disorders.
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              Alpha-synuclein and neurodegenerative diseases.

              M Goedert (2001)
                Bookmark

                Author and article information

                Journal
                J Exp Med
                J. Exp. Med
                jem
                jem
                The Journal of Experimental Medicine
                The Rockefeller University Press
                0022-1007
                1540-9538
                22 August 2016
                : 213
                : 9
                : 1759-1778
                Affiliations
                [1 ]Center for Neurodegenerative Science, Van Andel Research Institute, Grand Rapids, MI 49503
                [2 ]Bioinformatics and Biostatistics Core, Van Andel Research Institute, Grand Rapids, MI 49503
                [3 ]Roche Pharma Research & Early Development, Neuroscience Discovery, Roche Innovation Center, 4070 Basel, Switzerland
                [4 ]Department of Pathology and Laboratory Medicine, Institute on Aging and Center for Neurodegenerative Disease Research, University of Pennsylvania, Philadelphia, PA 19104
                Author notes
                Correspondence to Nolwen L. Rey: Nolwen.Rey@ 123456vai.org
                Author information
                http://orcid.org/0000-0003-0953-1310
                http://orcid.org/0000-0002-9611-041X
                http://orcid.org/0000-0002-6591-6269
                http://orcid.org/0000-0003-2330-0500
                http://orcid.org/0000-0002-9239-8794
                http://orcid.org/0000-0003-2924-5186
                Article
                20160368
                10.1084/jem.20160368
                4995088
                27503075
                52c6842b-85c2-4013-adbf-bdc13567da87
                © 2016 Rey et al.

                This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/3.0/).

                History
                : 10 March 2016
                : 16 June 2016
                Funding
                Funded by: European Research Council http://dx.doi.org/10.13039/501100000781
                Award ID: PRISTINE-PD 269064
                Funded by: Michael J. Fox Foundation http://dx.doi.org/10.13039/100000864
                Funded by: National Institutes of Health http://dx.doi.org/10.13039/100000002
                Award ID: NIA PO1 AG 17586-10
                Award ID: PO1 AG-032953
                Award ID: NINDS P50 NS053488-02
                Award ID: NIA UO1 AG029213-01
                Funded by: Cure Parkinson’s Trust http://dx.doi.org/10.13039/100008487
                Categories
                Research Articles
                Article

                Medicine
                Medicine

                Comments

                Comment on this article